Pharmaceuticals Industry Increasingly Partnering With MAb, Cancer and Other Biopharmaceuticals Companies to Boost Profits
The pharmaceutical industry increasingly is scouring the world in search of new molecular compounds to in- license to both their faltering pipelines at a time when new product introductions are at a historic low. Though big pharma has traditionally been associated with the discovery and development of small molecule therapeutics, it has increasingly become willing to in-license macromolecules from non- traditional sources, like the biotechnology industry, to both to their product lines.
The Oncology & Antibody Deal-Making Summit, now scheduled to take place on November 18-19, 2004 in Philadelphia, PA, and now in its second year -- is a unique partnering opportunity for pharmaceutical companies and their biotechnology counterparts that are producing monoclonal antibody therapeutics in record numbers and other macromolecules to complement the existing oral therapeutics to treat cancer, according to Strategic Research Institute.
This conference is an annual partnering forum that pairs big pharma and its small molecule heritage with the burgeoning macromolecule product lines that is being developed by antibody companies and others that develop macromolecule oncology & antibody therapeutics. The conference is structured in such a way that discrete presentations are complemented by a number of panels that will bring together big pharma and the biopharmaceutical companies developing these novel therapeutics and to talk about these deal structures, what the forecast is for deal-making in this area over the next 5 years, and other deal-making considerations such as whether to partner early on, and in the clinical development stage.
The inaugural meeting in 2003 was attended by the world industrial antibody and oncology communities from around the world and in 2004, this meeting offers a stellar lineup of speakers and panelists to address the most contemporary topics and engage in active discussion with the audience.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
